Your browser doesn't support javascript.
loading
Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
Miyamoto, Sho; Nishiyama, Takara; Ueno, Akira; Park, Hyeongki; Kanno, Takayuki; Nakamura, Naotoshi; Ozono, Seiya; Aihara, Kazuyuki; Takahashi, Kenichiro; Tsuchihashi, Yuuki; Ishikane, Masahiro; Arashiro, Takeshi; Saito, Shinji; Ainai, Akira; Hirata, Yuichiro; Iida, Shun; Katano, Harutaka; Tobiume, Minoru; Tokunaga, Kenzo; Fujimoto, Tsuguto; Suzuki, Michiyo; Nagashima, Maki; Nakagawa, Hidenori; Narita, Masashi; Kato, Yasuyuki; Igari, Hidetoshi; Fujita, Kaori; Kato, Tatsuo; Hiyama, Kazutoshi; Shindou, Keisuke; Adachi, Takuya; Fukushima, Kazuaki; Nakamura-Uchiyama, Fukumi; Hase, Ryota; Yoshimura, Yukihiro; Yamato, Masaya; Nozaki, Yasuhiro; Ohmagari, Norio; Suzuki, Motoi; Saito, Tomoya; Iwami, Shingo; Suzuki, Tadaki.
Afiliação
  • Miyamoto S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nishiyama T; Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi 464-8602, Japan.
  • Ueno A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Park H; Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi 464-8602, Japan.
  • Kanno T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nakamura N; Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi 464-8602, Japan.
  • Ozono S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Aihara K; International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo 113-0033, Japan.
  • Takahashi K; Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Tsuchihashi Y; Center for surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ishikane M; Center for Field Epidemic Intelligence, Research and Professional Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Arashiro T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
  • Saito S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ainai A; Center for surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Hirata Y; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Iida S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Katano H; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Tobiume M; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Tokunaga K; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Fujimoto T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki M; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nagashima M; Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nakagawa H; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
  • Narita M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
  • Kato Y; Department of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Igari H; Division of Infectious Diseases, Department of Internal Medicine, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa 901-1193, Japan.
  • Fujita K; Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba 286-0124, Japan.
  • Kato T; Department of Infection Control, Chiba University Hospital, Chiba, Japan.
  • Hiyama K; Department of Respiratory Medicine, National Hospital Organization Okinawa National Hospital, Okinawa 901-2214, Japan.
  • Shindou K; Department of Chest Disease, National Hospital Organization Nagara Medical Center, Gifu 502-8558, Japan.
  • Adachi T; Department of Infectious Disease, National Hospital Organization Fukuoka-Higashi Medical Center, Fukuoka 811-3195, Japan.
  • Fukushima K; Department of Pediatrics, Hirakata City Hospital, Osaka 573-1013, Japan.
  • Nakamura-Uchiyama F; Department of Infectious Diseases, Tokyo Metropolitan Toshima Hospital, Tokyo 173-0015, Japan.
  • Hase R; Department of Infectious Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 113-8677, Japan.
  • Yoshimura Y; Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Tokyo 130-8575, Japan.
  • Yamato M; Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba 286-8523, Japan.
  • Nozaki Y; Division of Infectious Disease, Yokohama Municipal Citizen's Hospital, Kanagawa 221-0855, Japan.
  • Ohmagari N; Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center 598-8577, Osaka, Japan.
  • Suzuki M; Department of Respiratory Medicine, Tokoname City Hospital, Aichi 479-8510, Japan.
  • Saito T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
  • Iwami S; Center for surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki T; Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Proc Natl Acad Sci U S A ; 120(52): e2314808120, 2023 Dec 26.
Article em En | MEDLINE | ID: mdl-38134196
ABSTRACT
Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that protect infectious virus shedding. Mucosal immunity prevents infection by SARS-CoV-2, which replicates in the respiratory epithelium and spreads rapidly to other hosts. However, whether mucosal immunity prevents the shedding of the infectious virus in SARS-CoV-2-infected individuals is unknown. We examined the relationship between viral RNA shedding dynamics, duration of infectious virus shedding, and mucosal antibody responses during SARS-CoV-2 infection. Anti-spike secretory IgA antibodies (S-IgA) reduced viral RNA load and infectivity more than anti-spike IgG/IgA antibodies in infected nasopharyngeal samples. Compared with the IgG/IgA response, the anti-spike S-IgA post-infection responses affected the viral RNA shedding dynamics and predicted the duration of infectious virus shedding regardless of the immune history. These findings highlight the importance of anti-spike S-IgA responses in individuals infected with SARS-CoV-2 for preventing infectious virus shedding and SARS-CoV-2 transmission. Developing medical countermeasures to shorten S-IgA response time may help control human-to-human transmission of SARS-CoV-2 infection and prevent future respiratory virus pandemics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
...